Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NeoTX Therapeutics

Request full access

Specialty biopharmaceutical company, with a focus on research and development in oncology immunotherapy

Rehovot, IsraelFounded 2015Biotech & Life Sciences

About NeoTX Therapeutics

NeoTX Therapeutics, an Israeli biopharmaceutical company founded in 2015, is a clinical-stage entity focused on immuno-oncology. The company was co-founded by CEO Asher Nathan, a seasoned entrepreneur in the biotechnology sector with over 25 patents to his name. Nathan, who holds a BSc in chemistry and biology, has founded other biotech companies like IntelliGene and EvoRx, the latter in collaboration with Nobel Laureates Arthur and Roger Kornberg. His extensive background in biotechnology and business strategy drives NeoTX's mission to develop novel cancer therapies.

The company's core business revolves around its proprietary Tumor Targeted Superantigen (TTS) platform, sometimes referred to as Selective T cell Redirection (STR). This technology is founded on the principle that the immune system is more effective at fighting bacteria than cancer. The platform works by coating a tumor with a bacterial derivative, specifically a superantigen, which tricks the immune system into mounting a powerful antibacterial response against the cancer cells. This approach aims to convert a weak anti-tumor response into a durable one, potentially benefiting patients who do not respond to existing immunotherapy treatments. NeoTX's business model involves in-licensing, developing, and commercializing these targeted anticancer immunotherapies, often through partnerships and collaborations with other pharmaceutical companies and clinical trial organizations.

NeoTX's lead product candidate is Naptumomab estafenatox (NAP), a TTS molecule licensed from Active Biotech in 2016. NAP is a fusion protein that targets the 5T4 antigen, which is present on a wide variety of solid tumors, including non-small cell lung cancer (NSCLC), pancreatic, and renal cell cancers. The molecule is designed to bind to these cancer cells and then activate a patient's T-cells to attack the tumor. NeoTX is evaluating NAP in multiple clinical trials, both as a monotherapy and in combination with other cancer treatments like chemotherapy and checkpoint inhibitors. For instance, a Phase 1b trial is assessing NAP in combination with AstraZeneca's durvalumab, and a Phase 2 trial is studying its use with docetaxel for NSCLC. The company has raised over $100 million in funding to advance these clinical programs and to in-license new technologies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
12
Open positions
None listed
Dealroom signal
36.8/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest May 2022
Capital deployed
—
Preferred round
ACQUISITION

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES C✓Equity / VC Feb 2020 $45M $180M Undisclosed ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

NeoTX Therapeutics website traffic

Latest recorded traffic for NeoTX Therapeutics is 2K monthly website visits, up 81.8% over the last three months. NeoTX Therapeutics's team declined 14.3% over the past year.

Latest monthly visits2K 3-month web change+81.8% 1-year team growth-14.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
AtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance L'Hospitalet de Llobregat, Spain Operational 10 $616K $2.5M
BAKX TherapeuticsWe create targeted cancer therapies through unique insights into the conformationally dynamic protein drivers of the mitochondrial apoptosis pathway combined with structure-based drug design and computational simulations Kingston, United States Closed
PrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy Jette, Belgium Operational
PROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables Cologne, Germany Operational
PhilogenDevelop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders Sovicille, Italy Operational
Persephone BiosciencesSynthetic biology company developing a platform to industrialize and scale the microbiome San Diego, United States Operational
ADCendoA Copenhagen-based biotech company dedicated to developing highly differentiated antibody-drug conjugates (ADCs) for the treatment of underserved cancers Copenhagen, Denmark Operational
Asgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming Lund Municipality, Sweden Operational
Showing 8 of the closest matchesCompare every metric →

NeoTX Therapeutics in the Rehovot ecosystem

Live from Dealroom

The NeoTX Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States33.3%
🇮🇱 Israel22.2%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NeoTX Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NeoTX Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.